methyl 2-chloro-4-methylpyrimidine-5-carboxylate | 1215922-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: methyl 2-chloro-4-methylpyrimidine-5-carboxylate
• CAS: 1215922-76-1
• 化学式: C₇H₇ClN₂O₂
• 分子量: 186.598
• InChiKey: XWDLJUGNAGKVEV-UHFFFAOYSA-N

物化性质

• 沸点：
  289.1±20.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-chloro-4-methylpyrimidine-5-carboxylate 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 methyl 4-[(E)-2-(dimethylamino)vinyl]-2-methoxypyrimidine-5-carboxylate
  参考文献：
  名称：

  WO2024182788A1

  摘要：

  公开号：

文献信息

• [EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2021257353A1

  公开（公告）日：2021-12-23

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

  本发明提供了一种式(I)的化合物，以及包括一种或多种所述化合物的药物组合物，并且使用所述化合物治疗或预防可能受益于抑制血浆激肽酶的一种或多种疾病状态的方法，包括遗传性血管性水肿、葡萄膜炎、后部葡萄膜炎、湿性老年性黄斑水肿、糖尿病性黄斑水肿、糖尿病视网膜病变和视网膜静脉阻塞。这些化合物是血浆激肽酶的选择性抑制剂。
• Bicyclic [3.3.0]-Octahydrocyclopenta[<i>c</i>]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease
  作者：Christopher L. Cioffi、Boglarka Racz、Emily E. Freeman、Michael P. Conlon、Ping Chen、Douglas G. Stafford、Daniel M. C. Schwarz、Lei Zhu、Douglas B. Kitchen、Keith D. Barnes、Nicoleta Dobri、Enrique Michelotti、Charles L. Cywin、William H. Martin、Paul G. Pearson、Graham Johnson、Konstantin Petrukhin

  DOI：10.1021/acs.jmedchem.5b00423

  日期：2015.8.13

  Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is associated with the pathogenesis of both dry age-related macular degeneration (AIVID) and Stargardt disease. Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant -vision loss associated with geographic atrophy of the macula. We previously disdosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocydopenta[c]pyrrolo analogue 4. We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33. Analogue 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).
• Herbicidally Active Pyridyl-/Pyrimidyl-Pyrimidine Derivatives
  申请人：Syngenta Participations AG

  公开号：US20200267981A1

  公开（公告）日：2020-08-27

  The present invention relates to herbicidal) active pyridyl-/pyrimidyl-pyridine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.
• [EN] HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2020035540A1

  公开（公告）日：2020-02-20

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.